 IRVINE, Calif., June 29, 2021 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis ALS, today announced that management will present a corporate overview at the virtual Ladenburg Thalmann Healthcare Conference on Tuesday, July 13 th at 2:00 pm EST. 